SCHEMBL1820409

SCHEMBL1820409

CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)NC(CC(C)C)C(=O)Oc1cc(C(F)(F)F)ccc1C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 2/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
FPR2 P25090 2/20 0.37
TP53 P04637 2/20 0.36
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
CTSL P07711 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
PSMB11 A5LHX3 1/20 0.33
PSMA7 O14818 1/20 0.33
PSMB1 P20618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820408 1.00 MAPT (0.40) MAPTALDH1A1NOS3NOS1NOS2
SCHEMBL5942129 0.92 ALDH1A1 (0.45) MAPTALDH1A1NOS3NOS1NOS2
SCHEMBL3434094 0.87 MAPK14 (0.35) MAPTALDH1A1NOS3NOS1NOS2
SCHEMBL5942243 0.87 ALDH1A1 (0.43) MAPTALDH1A1NOS3NOS1NOS2
SCHEMBL5942132 0.85 ALDH1A1 (0.44) MAPTALDH1A1TP53KDM4EUSP2
SCHEMBL19133163 0.85 MAPT (0.38) MAPTALDH1A1NOS3NOS1NOS2
SCHEMBL1823120 0.85 ALDH1A1 (0.44) MAPTALDH1A1TP53KDM4EHPGD
SCHEMBL21711009 0.85 ALDH1A1 (0.44) MAPTALDH1A1TP53KDM4EHPGD
SCHEMBL1819306 0.85 ALDH1A1 (0.44) MAPTALDH1A1TP53KDM4EHPGD
SCHEMBL1820208 0.85 KDM4E (0.42) MAPTALDH1A1TP53KDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2021-06-10 US disclosed
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2020-02-13 US disclosed
US-20180325923-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2018-11-15 US disclosed
EP-2813486-B1 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS INC (US) 2017-10-25 EP disclosed
EP-2315740-B1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS INC (US) 2017-10-25 EP disclosed
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2017-08-31 US disclosed
US-9708245-B2 Fatty acid acylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2017-07-18 US disclosed
US-9458094-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2016-10-04 US disclosed
US-9272984-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2016-03-01 US disclosed
US-9139516-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-8735378-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2014-05-27 US disclosed
US-8729293-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2014-05-20 US disclosed
US-20120238530-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-20120238586-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-20120238756-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-20120238585-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-8173831-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2012-05-08 US disclosed
EP-2315740-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES Catabasis Pharmaceuticals, Inc. (US) 2011-05-04 EP disclosed
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010006085-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20120238585-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20180325923-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20120238586-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20120238756-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885
US-20120238530-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 MAPT 2633/4885ALDH1A1 285/4885NOS3 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.